1 | Placebo IV | - | - | - | - | [1] 50 50 |
2 | Vedolizumab Intravenous (IV), Vedolizumab Subcutaneous (SC), Placebo IV | [1] Vedolizumab Vedolizumab | [1] D08083
D08083
| [2] ITGA4 ITGA4, ITGB7 💬 | [15] Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | [1] 97 97 |
3 | Vedolizumab IV, Placebo IV, Placebo SC | [1] Vedolizumab Vedolizumab | [1] D08083
D08083
| [2] ITGA4 ITGA4, ITGB7 💬 | [15] Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | [1] 97 97 |